A Study on the Impact of a Weekly Versus Three- Weekly Paclitaxel Schedule on Adverse Events in Patients with Solid Malignancies

2025-04-17T05:06:12+00:00

Cancer is one of the many illnesses that may affect any organ in the body. Cancer cells multiply more than they should.
Cancer ranks as the primary or secondary cause of death for those under the age of 70. The most common malignancies
worldwide are those of the lung, breast, esophagus, mouth, stomach, liver, and cervix uteri (cervix of the uterus). Paclitaxel
was the first known medication to stabilize microtubules and aid in cancer treatment. You can administer Paclitaxel IV
for three to twenty-four hours. To determine how each regimen impacts cancer patients’ quality of life as indicated by the
common terminology criteria for adverse events (CTCAE) scale, our main goal is to evaluate the severity of patients receiving
a weekly paclitaxel regimen compared to a three-week regimen. The SVS Medical College and Hospital Mahabubnagar
and Mahabubnagar Cancer Hospital served as the sites for this cross-sectional study. The compiled cases include patients
with solid malignancies. Every one of these patients would have a clinical PET scan at six months. We have analyzed the
collected data using reliable statistical techniques. Our research found that there was a higher risk of cancer development
in those between the ages of 40 and 50. Women are more likely than men to have solid cancers. The primary risk factors
for cancer are genetics, age, and family history. We divided 120 patients into two groups over six months. We administered
weekly paclitaxel to one group at a dosage of 130 mg for ninety minutes, and three weekly chemotherapy programs, each
containing 220 mg of paclitaxel spread out over three hours, to the other group. We found that weekly paclitaxel is more
effective than three weekly paclitaxels. Patients with lower adverse drug reactions received weekly paclitaxel rather than
three times a week. We have concluded that patients with solid malignancies benefit from weekly paclitaxel because it is
more efficacious and improves their quality of life. Increasing the dosage causes paclitaxel toxicity over three weeks, which
affects each person’s quality of life.

Development of Famotidine Swelling Matrix Tablets: In Vitro Evaluation and Release Kinetics Study

2025-04-15T12:59:52+00:00

The present study focuses on the formulation and evaluation of gastro-retentive swelling matrix tablets of Famotidine,
a histamine H₂-receptor antagonist with a short half-life and limited bioavailability. The aim was to develop a controlledrelease
dosage form to enhance gastric retention and sustain drug release over 24 hours. Various hydrophilic polymers
including HPMC K15M, HPMC K100M, Calcium CMC, Xanthan gum, and Avicel PH 101 were used to formulate six matrix
tablet batches (F1–F6) using the direct compression method. Preformulation studies confirmed the drug’s compatibility with
selected excipients through FTIR and DSC analysis. Micrometric properties such as angle of repose, compressibility index,
and Hausner’s ratio indicated good flow characteristics of the blend. All tablets were evaluated for physical parameters
including weight variation, thickness, hardness, friability, and content uniformity. In vitro, drug release studies conducted in
0.1 N HCl showed sustained release behavior across all formulations. F1 exhibited the fastest release (103.7% at 24 hrs),
while F3 had the most controlled profile (90.4% at 24 hrs). Kinetic modeling of the release data indicated that the Higuchi
model best described the release mechanism (R² = 0.969–0.998), suggesting diffusion-controlled drug release. The study
concluded that the swelling matrix system effectively sustained the release of famotidine and holds promise for once-daily
gastro-retentive dosage forms.

INTERNATIONAL JOURNAL OF APPLIED PHARMACEUTICAL SCIENCES AND RESEARCH

A Study on the Impact of a Weekly Versus Three- Weekly Paclitaxel Schedule on Adverse Events in Patients with Solid Malignancies

Development of Famotidine Swelling Matrix Tablets: In Vitro Evaluation and Release Kinetics Study